Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures

American Journal on Intellectual and Developmental Disabilities

Volumn 115, Issue 5, 2010, Pages 433-443

  Utari, Agustini ^a   Chonchaiya, Weerasak ^a   Rivera, Susan M ^a   Schneider, Andrea ^a   Hagerman, Randi J ^a   Faradz, Sultana M H ^b   Ethell, Iryna M ^c   Nguyen, Danh V ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DIPONEGORO UNIVERSITY   (Indonesia)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; MINOCYCLINE; NEUROPROTECTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; BEHAVIOR DISORDER; CHILD; FEMALE; FOLLOW UP; FRAGILE X SYNDROME; HUMAN; INFANT; LANGUAGE DISABILITY; MALE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD BEHAVIOR DISORDERS; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; FRAGILE X SYNDROME; HUMANS; INFANT; LANGUAGE DEVELOPMENT DISORDERS; MALE; MINOCYCLINE; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 77958192422     PISSN: 19447558     EISSN: None     Source Type: Journal    
DOI: 10.1352/1944-7558-115.5.433     Document Type: Review

References (68)

1. Abe, M., Furukawa, S., Takayama, S., Michitaka, K., Minami, H., & Yamamoto, K., et al. (2003). Drug-induced hepatitis with autoimmune features during minocycline therapy. Internal Medicine, 42, 48-52. (Pubitemid 36267664)
2. Akin, E., Miller, L. C., & Tucker, L. B. (1998). Minocycline-induced lupus in adolescent. Pediatrics, 101, 926-928.
3. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., Text Rev.). Washington DC: Author.
4. Ang, E. R., Zimmerman, J. C., & Malkin, E. (2002). Pseudotumor cerebri secondary to minocycline intake. Journal of the American Board of Family Practice, 15, 229-233.
5. Bantubungi, K., Jacquard, C., Greco, A., Pintor, A., Chtarto, A., & Tai, K. (2005). Minocycline in phenotypic models of Huntington's disease. Neurobiology of Disease, 18, 206-217. (Pubitemid 40092910)
6. Bassell, G. J., & Warren, S. T. (2008). Fragile X syndrome: Loss of local mRNA regulation alters synaptic development and function. Neuron, 60, 201-214.
7. Bear, M. F., Dolen, G., Osterweil, E., & Nagarajan, N. (2008). Fragile X: Translation in action. Neuropsychopharmacology, 33, 84-87. (Pubitemid 350191335)
8. Bear, M. F., Huber, K. M., & Warren, S. T. (2004). The mGluR theory of fragile X mental retardation. Trends in Neurosciences, 27, 370-377. (Pubitemid 38829251)
9. Bergles, D. E., & Jahr, C. E. (1998). Glial contribution to glutamate uptake at Schaffer collateral-commissural synapses in the hippocampus. Journal of Neuroscience, 18, 7709-7716. (Pubitemid 28441012)
10. Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., et al. (2009). A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. Journal of Medical Genetics, 46, 266-271.
11. Bilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., et al. (2009). Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. Journal of Medical Genetics, 46, 94-102.
12. Bowles, W. (1998). Protection againts minocycline pigment formation by ascorbic acid (vitamin C). Journal of Esthetic Dentistry, 10, 182-186. (Pubitemid 128770263)
13. Cascio, A., Di Liberto, C., D'Angelo, M., Iaria, C., Scarlata, F., Titone, L., et al. (2004). No findings of dental defects in children treated with minocycline. Antimicrobial Agents and Chemotherapy, 48, 2739-2741. (Pubitemid 38823456)
14. Choi, Y., Kim, H., Shin, K., Kim, E., Kim, M., & Kim, H., et al. (2007). Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology, 32, 2393-2404. (Pubitemid 47587688)
15. D'Hulst, C., Heulens, I., Brouwer, J. R., Willemsen, R., De Geest, N., Reeve, S. P., et al. (2009). Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Research, 1253, 176-183.
16. D'Hulst, C., & Kooy, R. F. (2007). The GABAA receptor: A novel target for treatment of fragile X? Trends in Neurosciences, 30, 425-431. (Pubitemid 47088715)
17. Danbolt, N. C. (2001). Glutamate uptake. Progress in Neurobiology, 65, 1-105. (Pubitemid 32479155)
18. Dansie L., Bilousova T., Ethell, D., & Ethell, I. (2009). [MMP-9 expression is regulated by mGluR5 activity in hippocampal neurons.] Unpublished raw data.
19. de Diego-Otero, Y., Romero-Zerbo, Y., el Bekay, R., Decara, J., Sanchez, L., Rodriguez-de Fonseca, F., et al. (2009). a-tocopherol protects against oxidative stress in the fragile X knockout mouse: An experimental therapeutic approach for the Fmr1 deficiency. Neuropsychopharmacology, 34, 1011-1026.
20. de Vrij, F. M., Levenga, J., van der Linde, H. C., Koekkoek, S. K., De Zeeuw, C. I., Nelson, D. L., et al. (2008). Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 knock-out mice. Neurobiology of Disease, 31, 127-132. (Pubitemid 351822560)
21. Eisen, D., & Hakim, M. D. (1998). Minocyclineinduced pigmentation. Incidence, prevention and management. Drug Safety, 18, 431-440.
22. El-Hallak, M., Giani, T., Yeniay, S. B., Jacobs, K. E., Kim, S., Sundel, R. P., et al. (2008). Chronic minocycline-induced autoimmunity in children. Journal of Pediatrics, 153, 314-319.
23. Elewa, H., Hilali, H., Hess, D., Machado, L., & Fagan, S. (2006). Minocycline for short-term neuroprotection. Pharmacotherapy, 24, 515-521.
24. Elkayam, O., Levartovsky, D., Brautbar, C., Yaron, M., Burke, M., Vardinon, N., et al. (1998). Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena. American Journal of Medicine, 105, 484-487. (Pubitemid 29013333)
25. Ethell, I. M., & Ethell, D. W. (2007). Matrix metalloproteinases in brain development and remodeling: Synaptic functions and targets. Journal of Neuroscience Research, 85, 2813-2823. (Pubitemid 47523564)
26. Farzin, F., Rivera, S. M., & Hessl, D. (2009). Brief report: Visual processing of faces in individuals with fragile X syndrome: An eye tracking study. Journal of Autism and Developmental Disorders, 39, 946-952.
27. Farzin, F., Whitney, D., Hagerman, R. J., & Rivera, S. M. (2008). Contrast detection in infants with fragile X syndrome. Vision Research, 48, 1471-1478.
28. Fernandez-Carvajal, I., Walichiewicz, P., Xiaosen, X., Pan, R., Hagerman, P. J., & Tassone, F. (2009). Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. Journal of Molecular Diagnostics, 11, 324-329.
29. Good, M. L., & Hussey, D. L. (2003). Minocycline: Stain devil? British Journal of Dermatology, 149, 237-239. (Pubitemid 37100246)
30. Gordon, P. H., Cheung, Y. K., Levin, B., Andrews, H., Doorish, C., Macarthur, R. B., et al. (2008). A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotrophic Lateral Sclerosis, 9, 212-222.
31. Hagerman, P. J. (2008). The fragile X prevalence paradox. Journal of Medical Genetics, 45, 498-499.
32. Hagerman, R. J. (2006). Lessons from fragile X regarding neurobiology, autism, and neurodegeneration. Journal of Developmental & Behavioral Pediatrics, 27, 63-74. (Pubitemid 44315121)
33. Hagerman, R. J., Rivera, S. M., & Hagerman, P. J. (2008). The fragile X family of disorders: A model for autism and targeted treatments. Current Pediatric Reviews, 4, 40-52. (Pubitemid 351513480)
34. Hessl, D., Berry-Kravis, E., Cordeiro, L., Yuhas, J., Ornitz, E. M., Campbell, A., et al. (2009). Prepulse inhibition in fragile X syndrome: Feasibility, reliability, and implications for treatment. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 150B, 545-553.
35. Imbesi, M., Uz, T., Manev, R., Sharma, R. P., & Manev, H. (2008). Minocycline increases phosphorylation and membrane insertion of neuronal GluR1 receptors. Neuroscience Letters, 447(2-3), 134-137.
36. Jonas, M. C. B. (1982). Minocycline. Therapeutic Drug Monitoring, 4, 137-145.
37. Kim, H. S., & Suh, Y. H. (2009). Minocycline and neurodegenerative diseases. Behavioral Brain Research, 196, 168-179.
38. Kooy, R. F. (2003). Of mice and the fragile X syndrome. Trends in Genetics, 19, 148-154. (Pubitemid 36279182)
39. Kriz, J., Nguyn, M. D., & Julien, J. (2002). Minocycline slows disease progression in a mouse model of amyotropic lateral sclerosis. Neurobiology of Disease, 10, 268-278. (Pubitemid 35217580)
40. LaPorta, V., Nikitakis, G., Sindler, A., & Reynolds, M. (2005). Minocycline-associated intra-oral soft tissue pigmentation: Clinicopathologic correlation and review. Journal of Clinical Periodotology, 32, 119-122. (Pubitemid 40341843)
41. Lawson, T., Amos, N., Bulgen, D., & Williams, B. (2001). Minocycline-induced lupus: Clinical features and response to rechallenge. Rheumatology, 40, 329-335.
42. Lee, S., Yune, T., Kim, S., Park, D., Lee, Y., & Kim, Y. (2003). Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. Journal of Neurotrauma, 20, 1017-1027. (Pubitemid 37288561)
43. Liu, Z., Fan, Y., Won, S., Neumann, M., Hu, M. D., Zhou, L., et al. (2007). Chronic treatment with minocycline preserves adult new neurons and reduces functional impairment after focal cerebral ischemia. Stroke, 38(146), 146-152. (Pubitemid 46035620)
44. Lord, C., Risi, S., Lambrecht, L., Cook, E. H., Jr., Leventhal, B. L., DiLavore, P. C., et al. (2000). The Autism Diagnostic Observation Schedule-Generic: A standard measure of social and communication deficits associated with the spectrum of autism. Journal of Autism and Developmental Disorders, 30, 205-223.
45. Lord, C., Rutter, M., & Le Couteur, A. (1994). Autism Diagnostic Interview-Revised: A revised version of a Diagnostic Interview for Caregivers of Individuals With Possible Pervasive Developmental Disorders. Journal of Autism and Developmental Disorders, 24, 659-685. (Pubitemid 24309810)
46. Margolis, D. J., Hoffstad, O., & Bilker, W. (2007). Association or lack of association between tetracycline class antibiotics used for acne vulgaris and lupus erythematosus. British Journal of Dermatology, 157, 540-546. (Pubitemid 47256131)
47. McBride, S. M., Choi, C. H., Wang, Y., Liebelt, D., Braunstein, E., Ferreiro, D., et al. (2005). Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron, 45, 753-764. (Pubitemid 40320709)
48. Nagarajan, L., & Lam, G. C. (2000). Tetracyclineinduced benign intracranial hypertension. Journal of Paediatrics Child Health, 36(1), 82-83.
49. Noble, W., Garwood, C., Stephenson, J., Kinsey, A., Hanger, D., & Anderton, B. M. (2009). Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. Journal of the Federation of American Societies For Experimental Biology (FASEB), 23, 739-750.
50. Oostra, B. A., & Willemsen, R. (2003). A fragile balance: FMR1 expression levels. Human Molecular Genetics, 12(Spec No. 2), R249-257. (Pubitemid 37259339)
51. Porter, D., & Harrison, A. (2003). Minocyclineinduced lupus: A case series. New Zealand Journal of Medicine, 116(1171). Available at http://www.nzma.org.nz/journal/116-1171/384/
52. Qin, M., Kang, J., Burlin, T. V., Jiang, C., & Smith, C. B. (2005). Postadolescent changes in regional cerebral protein synthesis: An in vivo study in the FMR1 null mouse. Journal of Neuroscience, 25, 5087-5095. (Pubitemid 40712853)
53. Sanchez, A., Rogers, R., & Sheridan, P. J. (2004). Tetracycline and other tetracycline-derivate staining of the teeth and oral cavity. International Journal of Dermatology, 43, 709-715. (Pubitemid 39405851)
54. Schlienger, R., Bircher, A., & Meier, C. (2000). Minocycline-induced lupus. Dermatology, 200, 223-231.
55. Shepherd, J. (2002). Severe complication of a commonly prescribed drug: Minocycline-induced lupus. Journal of the American Board of Family Medicine, 15, 239-241.
56. Shetty, A. (2002). Tetracyclines in pediatrics revisited. Clinical Pediatrics, 41, 203-209. (Pubitemid 34522474)
57. Shiri, J., & Amichai, B. (1997). Intracranial hypertension and minocycline. Annals of Internal Medicine, 127, 168.
58. Smith, K., & Leyden, J. (2005). Safety of doxycycline and minocycline: A systematic review. Clinical Therapeutics, 27, 1329-1342. (Pubitemid 41598368)
59. Sternlicht, M. D., & Werb, Z. (2001). How matrix metalloproteinases regulate cell behavior. Annual Review of Cell Developmental Biology, 17, 463-516. (Pubitemid 33096184)
60. Stirling, D., Khodarahmi, K., Liu, J., McPhail, L., McBride, C., & Steeves, J. (2004). Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. Journal of Neuroscience, 24, 2182-2190. (Pubitemid 38314550)
61. Sullivan, K., Hooper, S., & Hatton, D. (2007). Behavioural equivalents of anxiety in children with fragile X syndrome: Parent and teacher report. Journal of Intellectual Disability Research, 51(Pt 1), 54-65. (Pubitemid 44869818)
62. Teitelbaum, J., Atayde, A., Cohen, M., Bousvaros, A., & Jonas, M. (1998). Minocycline-related autoimmune hepatitis. Archives of Pediatrics & Adolescent Medicine, 152, 1132-1136.
63. Tournigand, C., Genereau, T., Prudent, M., Diemert, M., Herson, S., & Chosidow, O. (1999). Minocycline-induced clinical and biological lupus-like disease. Lupus, 8, 773-774.
64. Tredwin, C. J., Scully, C., & Bagan-Sebastian, J. V. (2005). Drug-induced disorders of teeth. Journal of Dental Research, 84, 596-602. (Pubitemid 43827838)
65. van Steensel, M. A. (2004). Why minocycline can cause systemic lupus-A hypothesis and suggestions for therapeutic interventions based on it. Medical Hypotheses, 63, 31-34. (Pubitemid 38887107)
66. Verkerk, A. J., Pieretti, M., Sutcliffe, J. S., Fu, Y. H., Kuhl, D. P., Pizzuti, A., et al. (1991). Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell, 65, 905-914 (Pubitemid 121001321)
67. Wang, J. Q., Arora, A., Yang, L., Parelkar, N. K., Zhang, G., Liu, X., & Mao, L. (2005). Phosphorylation of AMPA receptors: Mechanisms and synaptic plasticity. Molecular Neurobiology, 32, 237-249. (Pubitemid 41749422)
68. Well, J., Hulbert, R., Fehling, M., & Yong, V. (2003). Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain, 126, 1628-1637. (Pubitemid 36834939)